CAS: 16265-11-5; 4-Bromo-2-Methyl-1H-Imidazole

该化合物是一种杂交有机化合物,其特征是一环有5个环,内含两个氮原子;4位置有溴原子,2位置有甲基组,其独特的化学特性是:该化合物一般是白色到浅黄色的固体,在水和酒精等极溶剂中可溶解;它显示出因一环的氮原子而具有的基本特性,因此有可能成为各种化学反应的候选体,包括核哲学替代和与金属离子的协调. 4-Bromo-2-Mephyimidazole经常用于药物研究和有机合成的建筑块,特别是用于发展生物活性化合物.其反应和功能化潜力使其在医药化学和材料科学中具有价值.在处理该化合物时,应当采取安全防范措施,因为如果浸泡或吸入,可能会对健康造成危害.

结构式图片

相似化合物

4002-81-7 1260876-31-0 1643537-99-8

欧盟法规

ECHA物质C&L通报

上下游产品

4,5-Dibromo-2-methylimidazole 2-methylimidazole 5-bromo-1,2-dimethyl-1H-imidazole 2-methyl-4-phenyl-1H-imidazole 4-bromo-1,2-dimethyl-1H-imidazole

合成工艺路线路线简述

    4,5-二溴-2-甲基咪唑置于sodium Sulfite体系中,化学反应生成4-溴-2-甲基咪唑
    参考文献:Light; Pyman,Journal Of The Chemical Society,1922,Vol. 121,P. 2628
    标题:Light; Pyman,Journal Of The Chemical Society,1922,Vol. 121,P. 2628

    专利信息


    专利号:US-10226449-B2
    优先权日:2013-12-20
    标 题:Heterocyclic modulators of lipid synthesis and combinations thereof
    发明人:HEUER TIMOTHY SEAN; OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREGORY; OHOL-GUPTA YAMINI; O'FARRELL MARIE
    权利人:3 V BIOSCIENCES INC
    摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

    专利号:US-9428502-B2
    优先权日:2012-07-03
    标题:Heterocyclic modulators of lipid synthesis
    发明人:OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; WAGMAN ALLAN S
    权利人:3-V BIOSCIENCES INC
    摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

    专利号:WO-2023091726-A1
    优先权日:2021-11-18
    标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
    发明人:BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
    权利人:SYROS PHARMACEUTICALS INC
    摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

    专利号:US-2018222892-A1
    优先权日:2012-07-03
    标 题 :Heterocyclic modulators of lipid synthesis

    专利号:EP-3083583-B1
    优先权日:2013-12-20
    标 题:Heterocyclic modulators of lipid synthesis and combinations thereof

    专利号:CA-2934251-A1
    优先权日:2013-12-20
    标题:A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer
    北京偶合科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.ouhechem.com
    企业联系电话:010-51280831(不占线);010-82967028👤
    📞北京偶合科技有限公司 ⚠️参考联系方式
    联系人:刘先生
    电话:010-51280831(不占线);010-82967028
    手机:13911808554
    传真:010-82967029
    邮箱:sales@ouhechem.com
    通信地址: 北京市海淀区西三旗桥东上奥世纪2b-1328室
    邮编: 100096
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:北京市海淀区西三旗桥东上奥世纪2b-1328室
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1007/s11030-014-9551-5
    摘要:Safa KD, Allahvirdinesbat M, Namazi H. Synthesis of novel organosilicon compounds possessing highly substituted imidazole core catalyzed by antimony trioxide. Mol Divers. 2015 Feb;19(1):29–41. doi: 10.1007/s11030-014-9551-5.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知